Research in hematology is conducted by numerous faculty members, residents, post-doctoral candidates, and technicians.
Learn More About Hematology
Recent clinical-trial research conducted in the Penn State Health Division of Hematology has included:
- A Phase III study to evaluate the efficacy, safety and pharmacokinetics of prophylactic Emicizumab versus no prophylaxis in hemophilia A patients with inhibitors
- A study of a long-acting r-factor 7a (factor VIIa) in adult men with hemophilia A or B
- Safety and efficacy of BAY94-9027 in previously treated male children with hemophilia A
- Sirolimus and Cyclosporine for treatment-resistant aplastic anemia
- A Phase 3/4 study of a recombinant protein-free factor VIII (rAHF-PFM), comparing continuous infusion versus intermittent bolus infusion in hemophilia A subjects undergoing major orthopedic surgery
The Hemophilia and Thrombosis Center of Central Pennsylvania is run by the Penn State Health Division of Hematology and provides a medical home for patients with inherited bleeding disorders including hemophilia and von Willebrand disease.
See details on treatments provided by the Hemophilia and Thrombosis Center here.
M. Elaine Eyster, MD, FACP, is Director of the Hemophilia and Thrombosis Center of Central Pennsylvania.
To speak to someone about hematology research, please call 717-531-7710.